New association between agomelatine and a thymoregulatory agent and pharmaceutical compositions containing it

摘要

#CMT# #/CMT# Association comprises: agomelatine (N-[2-(7-methoxy-1-naphtyl)ethyl]acetamide) or its hydrate, crystalline, acid or base salts; and thymoregulating agent. #CMT#ACTIVITY : #/CMT# Hypnotic; Antidepressant; Cardiovascular-Gen; Neuroleptic; Anorectic; Gastrointestinal-Gen; CNS-Gen. #CMT#MECHANISM OF ACTION : #/CMT# Melatoninergic receptor system agonist; Hydroxytryptamine receptor antagonist. #CMT#USE : #/CMT# The association is useful to prepare the pharmaceutical composition or a medicament to treat mood disorders (claimed) e.g. dysthymia, cyclothymia, depression, irritability or excessive anger, culpability, loss of interest, chronic tiredness, decline of social activity and bad concentration. The association is also useful to treat central nervous system disorders, particularly depressive disorders, seasonal depressions, cardiovascular pathology, sleep disorders, disorders of digestive system, insomnia and tirednesses due to shifts, appetite disorders and obesity. Tests details are described but no results given. #CMT#ADVANTAGE : #/CMT# (I) has a double effect on the melatoninergic receptor system agonist and hydroxytryptamine receptor antagonist. #CMT#PHARMACEUTICALS : #/CMT# Preferred Components: The thymoregulating agent is valproate. #CMT#ADMINISTRATION : #/CMT# Administration of agomelatine 1-50 mg/day, preferably 25 mg/day, orally, parenterally, nasally or sublingually. #CMT#EXAMPLE : #/CMT# Typical composition comprised (in g): N-[2-(7-methoxy-1-naphtyl)ethyl] acetamide (25); lactose monohydrate (62); magnesium stearate (1.3); povidone (9); colloidal silica anhydride (0.3); sodium glycolate cellulose (30); and stearic acid (2.6).